Premier Biomedical, Inc

Premier Biomedical Develops Patented Application and FDA Filing for Duchenne Muscular Dystrophy


El Paso, TX -- (SBWIRE) -- 02/25/2015 -- Premier Biomedical, Inc. (OTCQB:BIEI) announced that they have developed and filed a Request for Designation of Duchenne Muscular Dystrophy as a rare disease, preparing the way for a formal "Humanitarian Use Device" (HUD) application for Premier's treatment and potential cure for the disease. A United States Patent application for this treatment methodology was filed in the third quarter of 2014.

William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, "There is no known cure for Duchenne Muscular Dystrophy, at this time. There are over one million cases worldwide and treatment costs exceed $23 billion annually. Our filing of an application for a Humanitarian Use Device would expedite the availability of this treatment to patients, since the HUD program creates and alternative pathway for getting market approval."

"We are currently awaiting a decision on our Request for Designation of Duchenne Muscular Dystrophy with the FDA," Hartman continued. "Our on-going research and development using our patented technology to cure diseases using antibodies against disease antigens, on bodily fluids treated outside the body, offers hope for those afflicted by this dreaded disease, as well as other incurable diseases."

Duchenne Muscular Dystrophy (DMD) is a recessive X-linked form of muscular dystrophy, and affects 1 in 3,500 births. The condition is mostly seen in males, which results in muscle degeneration and eventual death. Both males and females can carry the mutation; however, females rarely exhibit signs of the disease.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI"

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Premier Biomedical, Inc
W. Hartman
Email Contact

Source: UPTICK Newswire